The Danish Melanoma Database

Lisbet Rosenkrantz Hölmich; Siri Klausen; Eva Spaun; Grethe Schmidt; Dorte Gad; Inge Marie Svane; Henrik Schmidt; Henrik Frank Lorentzen; Else Helene Ibfelt

doi:10.2147/CLEP.S99484

The Danish Melanoma Database

Lisbet Rosenkrantz Hölmich, Siri Klausen, Eva Spaun, Grethe Schmidt, Dorte Gad, Inge Marie Svane, Henrik Schmidt, Henrik Frank Lorentzen, Else Helene Ibfelt

Department of Clinical Medicine

11 Citations (Scopus)

Abstract

AIM OF DATABASE: The aim of the database is to monitor and improve the treatment and survival of melanoma patients.

STUDY POPULATION: All Danish patients with cutaneous melanoma and in situ melanomas must be registered in the Danish Melanoma Database (DMD). In 2014, 2,525 patients with invasive melanoma and 780 with in situ tumors were registered. The coverage is currently 93% compared with the Danish Pathology Register.

MAIN VARIABLES: The main variables include demographic, clinical, and pathological characteristics, including Breslow's tumor thickness, ± ulceration, mitoses, and tumor-node-metastasis stage. Information about the date of diagnosis, treatment, type of surgery, including safety margins, results of lymphoscintigraphy in patients for whom this was indicated (tumors > T1a), results of sentinel node biopsy, pathological evaluation hereof, and follow-up information, including recurrence, nature, and treatment hereof is registered. In case of death, the cause and date are included. Currently, all data are entered manually; however, data catchment from the existing registries is planned to be included shortly.

DESCRIPTIVE DATA: The DMD is an old research database, but new as a clinical quality register. The coverage is high, and the performance in the five Danish regions is quite similar due to strong adherence to guidelines provided by the Danish Melanoma Group. The list of monitored indicators is constantly expanding, and annual quality reports are issued. Several important scientific studies are based on DMD data.

CONCLUSION: DMD holds unique detailed information about tumor characteristics, the surgical treatment, and follow-up of Danish melanoma patients. Registration and monitoring is currently expanding to encompass even more clinical parameters to benefit both patient treatment and research.

Original language	English
Journal	Clinical Epidemiology
Volume	8
Pages (from-to)	543-548
Number of pages	6
ISSN	1179-1349
DOIs	https://doi.org/10.2147/CLEP.S99484
Publication status	Published - 25 Oct 2016

Keywords

Review
Journal Article

Access to Document

10.2147/CLEP.S99484Licence: CC BY-NC

Cite this

@article{eaef3cb38aa04971aaea5db35a7b8bcb,

title = "The Danish Melanoma Database",

abstract = "AIM OF DATABASE: The aim of the database is to monitor and improve the treatment and survival of melanoma patients.STUDY POPULATION: All Danish patients with cutaneous melanoma and in situ melanomas must be registered in the Danish Melanoma Database (DMD). In 2014, 2,525 patients with invasive melanoma and 780 with in situ tumors were registered. The coverage is currently 93% compared with the Danish Pathology Register.MAIN VARIABLES: The main variables include demographic, clinical, and pathological characteristics, including Breslow's tumor thickness, ± ulceration, mitoses, and tumor-node-metastasis stage. Information about the date of diagnosis, treatment, type of surgery, including safety margins, results of lymphoscintigraphy in patients for whom this was indicated (tumors > T1a), results of sentinel node biopsy, pathological evaluation hereof, and follow-up information, including recurrence, nature, and treatment hereof is registered. In case of death, the cause and date are included. Currently, all data are entered manually; however, data catchment from the existing registries is planned to be included shortly.DESCRIPTIVE DATA: The DMD is an old research database, but new as a clinical quality register. The coverage is high, and the performance in the five Danish regions is quite similar due to strong adherence to guidelines provided by the Danish Melanoma Group. The list of monitored indicators is constantly expanding, and annual quality reports are issued. Several important scientific studies are based on DMD data.CONCLUSION: DMD holds unique detailed information about tumor characteristics, the surgical treatment, and follow-up of Danish melanoma patients. Registration and monitoring is currently expanding to encompass even more clinical parameters to benefit both patient treatment and research.",

keywords = "Review, Journal Article",

author = "H{\"o}lmich, {Lisbet Rosenkrantz} and Siri Klausen and Eva Spaun and Grethe Schmidt and Dorte Gad and Svane, {Inge Marie} and Henrik Schmidt and Lorentzen, {Henrik Frank} and Ibfelt, {Else Helene}",

year = "2016",

month = oct,

day = "25",

doi = "10.2147/CLEP.S99484",

language = "English",

volume = "8",

pages = "543--548",

journal = "Clinical Epidemiology",

issn = "1179-1349",

publisher = "Dove Medical Press Ltd",

}

TY - JOUR

T1 - The Danish Melanoma Database

AU - Hölmich, Lisbet Rosenkrantz

AU - Klausen, Siri

AU - Spaun, Eva

AU - Schmidt, Grethe

AU - Gad, Dorte

AU - Svane, Inge Marie

AU - Schmidt, Henrik

AU - Lorentzen, Henrik Frank

AU - Ibfelt, Else Helene

PY - 2016/10/25

Y1 - 2016/10/25

N2 - AIM OF DATABASE: The aim of the database is to monitor and improve the treatment and survival of melanoma patients.STUDY POPULATION: All Danish patients with cutaneous melanoma and in situ melanomas must be registered in the Danish Melanoma Database (DMD). In 2014, 2,525 patients with invasive melanoma and 780 with in situ tumors were registered. The coverage is currently 93% compared with the Danish Pathology Register.MAIN VARIABLES: The main variables include demographic, clinical, and pathological characteristics, including Breslow's tumor thickness, ± ulceration, mitoses, and tumor-node-metastasis stage. Information about the date of diagnosis, treatment, type of surgery, including safety margins, results of lymphoscintigraphy in patients for whom this was indicated (tumors > T1a), results of sentinel node biopsy, pathological evaluation hereof, and follow-up information, including recurrence, nature, and treatment hereof is registered. In case of death, the cause and date are included. Currently, all data are entered manually; however, data catchment from the existing registries is planned to be included shortly.DESCRIPTIVE DATA: The DMD is an old research database, but new as a clinical quality register. The coverage is high, and the performance in the five Danish regions is quite similar due to strong adherence to guidelines provided by the Danish Melanoma Group. The list of monitored indicators is constantly expanding, and annual quality reports are issued. Several important scientific studies are based on DMD data.CONCLUSION: DMD holds unique detailed information about tumor characteristics, the surgical treatment, and follow-up of Danish melanoma patients. Registration and monitoring is currently expanding to encompass even more clinical parameters to benefit both patient treatment and research.

AB - AIM OF DATABASE: The aim of the database is to monitor and improve the treatment and survival of melanoma patients.STUDY POPULATION: All Danish patients with cutaneous melanoma and in situ melanomas must be registered in the Danish Melanoma Database (DMD). In 2014, 2,525 patients with invasive melanoma and 780 with in situ tumors were registered. The coverage is currently 93% compared with the Danish Pathology Register.MAIN VARIABLES: The main variables include demographic, clinical, and pathological characteristics, including Breslow's tumor thickness, ± ulceration, mitoses, and tumor-node-metastasis stage. Information about the date of diagnosis, treatment, type of surgery, including safety margins, results of lymphoscintigraphy in patients for whom this was indicated (tumors > T1a), results of sentinel node biopsy, pathological evaluation hereof, and follow-up information, including recurrence, nature, and treatment hereof is registered. In case of death, the cause and date are included. Currently, all data are entered manually; however, data catchment from the existing registries is planned to be included shortly.DESCRIPTIVE DATA: The DMD is an old research database, but new as a clinical quality register. The coverage is high, and the performance in the five Danish regions is quite similar due to strong adherence to guidelines provided by the Danish Melanoma Group. The list of monitored indicators is constantly expanding, and annual quality reports are issued. Several important scientific studies are based on DMD data.CONCLUSION: DMD holds unique detailed information about tumor characteristics, the surgical treatment, and follow-up of Danish melanoma patients. Registration and monitoring is currently expanding to encompass even more clinical parameters to benefit both patient treatment and research.

KW - Review

KW - Journal Article

U2 - 10.2147/CLEP.S99484

DO - 10.2147/CLEP.S99484

M3 - Journal article

C2 - 27822097

SN - 1179-1349

VL - 8

SP - 543

EP - 548

JO - Clinical Epidemiology

JF - Clinical Epidemiology

ER -

The Danish Melanoma Database

Abstract

Keywords

Access to Document

Fingerprint

Cite this